The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•1 May 2026•

1 min read

InspireMD Receives FDA Approval to Initiate SwitchGuard Pivotal Study

Key Facts

1The U.S. Food and Drug Administration (FDA) approved InspireMD's Investigational Device Exemption (IDE) application to initiate the CGUARDIANS III pivotal study.

InspireMD, Inc. has announced that it received approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE) application to initiate the CGUARDIANS III pivotal study. This clinical trial is designed to evaluate the SwitchGuard neuro protection system (NPS) specifically for use in transcarotid artery revascularization (TCAR) procedures. The study will test the SwitchGuard system in conjunction with the CGuard Prime stent platform to determine its safety and efficacy in stroke prevention. This regulatory milestone represents a significant advancement for the company's vascular intervention pipeline. The approval allows InspireMD to move forward with critical clinical data collection required for future commercial expansion. Investors are closely monitoring the trial's progress as a key driver for the company's long-term valuation in the medical device sector.

Sources: